ASCO Genitourinary Cancers Symposium
ASCO GU 2022 on a Study EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC
By
ASCO Genitourinary Cancers Symposium
FEATURING
Daniel Petrylak
By
ASCO Genitourinary Cancers Symposium
FEATURING
Daniel Petrylak
Login to view comments.
Click here to Login